Articles tagged with Kidney Cancer
Researchers have developed a first-of-its-kind molecular test kit that can predict treatment and survival outcomes in kidney cancer patients based on their tumor profile. The assay was able to distinguish patients into groups with different survival and treatment outcomes, allowing for more educated choices in treatment options.
A study published in Nature Communications found that pseudogene expression profiles can help explain how cancer occurs and aid in discovering new biomarkers. This knowledge is crucial for developing targeted therapies and predicting patient outcomes.
Researchers have uncovered 31 genes crucial to the development, growth, and spread of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. The study found eight previously unlinked genes and six unknown to any cancer type, highlighting potential new therapeutic targets.
Researchers at Mayo Clinic discovered that the NPTX2 gene is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer. The study reveals that NPTX2 plays a key role in this cancer type, which is resistant to chemotherapy and has a low five-year overall survival rate.
New research links low blood cholesterol to more advanced tumor stages and reduced cancer survival rates in kidney cancer patients. High cholesterol levels are associated with a lower risk of death from the disease, suggesting a potential new prognostic tool for monitoring patient outcomes.
A retrospective study of over 1.2 million adults found that reduced glomerular filtration rate is an independent risk factor for renal and urothelial cancer, but not other types of cancer. Lower GFR levels were associated with increased rates of incident renal cancer and urothelial cancer.
Individuals with poor kidney function have a higher risk of developing kidney and urothelial cancers, according to a recent study. The study found that those with lower estimated glomerular filtration rates (eGFR) had a significant increase in cancer risk, particularly for renal cell carcinoma.
Chronic kidney disease is associated with a higher risk of developing renal and urothelial cancers. A recent study found that patients with reduced glomerular filtration rates were more likely to develop these types of cancer, particularly those with severe chronic kidney disease.
Research suggests that patients with polycystic kidney disease (PKD) who undergo a kidney transplant may be less likely to develop cancer compared to those without PKD. The study found that PKD patients were 16% less likely to develop cancer than others who received a kidney transplant, and their overall cancer risk was 48% lower than ...
Using a novel bioinformatics approach, researchers have found that the approved antimicrobial drug pentamidine may help treat advanced kidney cancer. The study identified gene expression patterns that suggest an antimicrobial may be effective against clear cell renal cancer, a common and highly malignant subtype of kidney cancer.
Renal cancer cells grow rapidly when placed in a pro-growth matrix supported by an enzyme typically found in the brain. Inhibiting this kinase halts cancer cell division and spread, suggesting its role in cancer growth.
Researchers found that hypoxia stimulates the mislocation of SPOP to the cytoplasm, promoting rapid tumor growth. This shift enables SPOP to degrade key tumor-suppressor proteins, such as PTEN, leading to cancer progression. Understanding this mechanism may lead to new therapeutic approaches.
Researchers have found a potential new treatment for patients with advanced melanoma and kidney cancer. The study used an antibody that targets the tumor-enhancing protein TGFβ, which is involved in cell growth and spread of tumors.
A new Phase III clinical trial at Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute aims to provide kidney cancer patients with long-term control of their disease. The vaccine-based approach uses a patient's own immune system to fight the disease, potentially improving survival outcomes and quality of life.
Kidney cancer cells exhibit distinct metabolic differences compared to other cancers, providing a potential weak link for diagnosis and treatment. This discovery opens the door to new biomarkers and therapeutic approaches for detecting kidney cancer at an early stage.
Dr. Walter Quan from Cancer Treatment Centers of America (CTCA) presents two new treatment options for previously-treated advanced cancer patients, showing major benefits with minimal side effects. The first treatment involves combination chemoimmunotherapy, while the second utilizes dose-dense outpatient intravenous Interleukin-2.
The Phase II study showed that everolimus successfully slowed or prevented disease spread in 59% of patients. Everolimus may represent a new treatment option for advanced papillary kidney cancer, which accounts for 15% of all kidney cancer cases.
Adult childhood cancer survivors who underwent nephrotoxic therapies or kidney surgery had worse kidney function that did not recover over time. The study found a significant decline in glomerular function after treatment and a higher risk of premature chronic renal failure.
A large international clinical trial found pazopanib to be superior to sunitinib in terms of quality of life, with fewer side effects and lower risk of complications. The study's results suggest that pazopanib may become the preferred treatment for advanced kidney cancer patients.
A team of Singaporean and Taiwanese scientists have discovered that Aristolochic Acid (AA), a natural compound found in traditional Asian herbal remedies, is the most potent carcinogen identified to date, causing extensive DNA mutations. The study also reveals AA's possible link to liver cancer and calls for increased public awareness ...
A recent URMC study questions the assumption that saving kidney tissue during surgery improves patient outcomes and survival rates, suggesting radical nephrectomy may be a viable option for certain patients with small kidney cancers.
Every year, around 700 women with urinary cancers are missing out on prompt diagnosis due to initial misattribution by family doctors. Women were twice as likely to have visited their GP multiple times before being referred to a specialist, leading to delayed diagnoses and poorer survival rates.
Scientists have discovered a connection between the aggressiveness of kidney cancer and changes in how tumor cells use energy from metabolic processes. The study found that certain proteins are associated with worse patient outcomes, while others may be used as therapeutic targets.
Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are testing the safety of Nivolumab, a PD-1 receptor blocking antibody, in combination with other drugs in patients with metastatic renal cell carcinoma. The study aims to assess safety and tolerability, as well as preliminary antitumor activity.
A cohort study published in JNCI found a statistically significant elevated standardized incidence ratio for primary liver cancer among workers exposed to trichloroethylene. However, no significant risk was observed for kidney cancer or non-Hodgkin lymphoma. The authors suggest that further research is needed to confirm these findings.
Researchers at Mayo Clinic discover a protein that is overly active in every human sample of kidney cancer and find an experimental drug designed to block its activity significantly reduces tumor growth. Combining it with another drug improves effectiveness.
A new study shows that chemical shift techniques in MRI can accurately differentiate clear cell renal cell carcinoma from other types of kidney cancer, enabling better treatment planning. The technique achieved an 83% accuracy rate in distinguishing between tumor types.
Researchers at UCLA have classified kidney cancer into several unique subtypes, which will aid in tailoring treatment to individual patients. The study, conducted over 10 years, identified deletions of chromosomes 3p and 14q in clear cell renal carcinoma tumors, associated with improved survival rates for some patients.
James Mier's research focuses on tumor angiogenesis in renal cell carcinomas and overcoming resistance to VEGF inhibition. He aims to block the dual-survival strategy of kidney cancer using HDM2 inhibitors and VEGF-targeted drugs.
Researchers at UC Riverside have developed a compound called TIR-199 that targets the proteasome complex in kidney cancer cells, showing promising results in laboratory tests. The compound is nearly as potent as existing bortezomib but selectively inhibits growth of only renal cancer cell lines.
Research from the 2013 Genitourinary Cancers Symposium highlights new insights on high-risk prostate cancer prevalence and treatment. Studies show that African-American men and older men of any race are more likely to have aggressive prostate cancer, while surveillance for small kidney tumors is a safe alternative to surgery for elderl...
Researchers found that microscopic hematuria does not necessarily indicate cancer, and patients with this condition may avoid unnecessary tests. A new model, the Hematuria Risk Index, predicts renal and bladder cancer risk, reducing unnecessary work-ups.
Drs. William Y. Kim and James W. Mier have received $250,000 grants to conduct innovative translational kidney cancer research. Their projects aim to personalize kinase therapy and explore the mechanism of HDM2 antagonists in blocking tumor angiogenesis.
Researchers at Henry Ford Hospital have developed a new technique for minimally invasive robotic partial nephrectomy procedures, sparing the kidney and eliminating long hospital stays. The technique, called ICE, provides better outcomes by giving surgeons more time to perform the procedure and allows for better tumor removal and analysis.
A team of researchers at St. Michael's Hospital has discovered multiple ways kidney tumours can achieve the same result – namely, grow. By examining chromosomal changes, methylation, and gene expression, they identified specific regions where genetic alterations occur in kidney cancer.
A new study found that black patients with kidney cancer have a survival disadvantage compared to white patients, even when diagnosed at early stages or receiving less aggressive treatment. The study analyzed nearly 40,000 renal cell carcinoma patients and confirmed poorer survival rates for blacks.
A Phase 1 clinical trial has shown encouraging results for stereotactic radiosurgery in treating localized primary renal cancer, with 94% of patients experiencing decreased or stable disease and limited side effects. The non-invasive treatment technique may represent a potential new option for patients who have limited treatment options.
The Asian Oncology Summit guidelines emphasize the importance of providing supportive, palliative and end-of-life care to patients with cancer in Asia. The guidelines provide recommendations for pain assessment, medication, professional education, and specialized interventions tailored to different levels of resources in Asian countries.
A recent study suggests that active surveillance is a viable alternative to surgery for small kidney masses, offering similar cancer outcomes in the short and intermediate term. Researchers found that patients under active surveillance had a growth rate of 0.21cm per month, with 53% showing no growth.
Phase III trials have reported promising results for the treatment of renal cell carcinoma, with pazopanib and temsirolimus emerging as effective options. Pazopanib was shown to be non-inferior to sunitinib in controlling metastatic renal cell carcinoma, resulting in fewer troublesome side effects and improved quality of life.
Researchers at UC San Diego School of Medicine found that single-site laparoscopic surgery reduced pain and narcotic use in kidney cancer patients. The study compared LESS with traditional multiport laparoscopy in 74 patients, showing a 40% reduction in pain rating and 50% less medication need.
A blood test detecting high levels of lactate dehydrogenase (LDH) may guide treatment for advanced kidney cancer, extending survival and improving outcomes for patients. Researchers found that LDH levels can predict the effectiveness of mTOR inhibitor temsirolimus in treating late-stage kidney cancer.
A new approach to treating triple negative breast cancer and clear cell renal cell carcinoma has been discovered by researchers at Mayo Clinic. The approach involves activating a potent tumor suppressor gene called sFRP1, which is silenced in these cancers. Once activated, the laboratory tumor cells stopped growing and died.
The AACR-Kure It Grant will support innovative kidney cancer research, aiming to improve patient survival and quality of life. The grant recipient will receive $250,000 over two years and recognition at the AACR Annual Meeting.
A new treatment protocol for kidney cancer uses molecular imaging and radioimmunotherapy to target clear cell renal carcinoma. The study found that the effectiveness of this therapy may be diminished when used after another anti-cancer drug, sorafenib.
A new antibody treatment has shown promising activity in patients with advanced kidney cancer, melanoma and lung cancer. Patients who received the treatment experienced a positive response without severe side effects.
A team of researchers at UC Davis has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. The study used metabolomics techniques to analyze chemicals in urine and serum samples from mice implanted with human kidney cancer cells.
A new study found that folic acid fortification of foods may lower the incidence of certain types of childhood cancer in the US. Incidence reductions were found for Wilms' tumor and primitive neuroectodermal tumors, two types of cancer previously associated with neural tube defects.
Researchers from the University of Minnesota and Washington University found that folic acid fortification of grain products does not increase childhood cancer rates but may be protective against certain cancers. A notable decrease in Wilms tumor and primitive neuroectodermal tumor was observed following the start of fortification.
A new study by Henry Ford Hospital urologists finds that robot-assisted partial nephrectomy (RAPD) offers fewer complications than laparoscopic partial nephrectomy (LPN), but notes limitations due to data availability on surgical expertise and cancer complexity. The procedure has become the standard treatment for kidney cancer, with co...
A new study found that safer partial nephrectomy surgery is less common among older, sicker, and poorer patients who rely on Medicare or Medicaid for care. This disparity may be due to limited access to care or lower proficiency in performing the advanced surgical technique.
A new University of Michigan study found that patients with early-stage kidney cancer who underwent partial nephrectomy had better survival rates than those who received radical nephrectomy. The study analyzed data from 7,138 Medicare beneficiaries and showed that younger or medically compromised patients benefited most from the less i...
Researchers identify two distinct autophagy-regulated pathways downstream from the von Hippel-Lindau tumor suppressor gene in kidney cancer. This discovery could lead to more effective treatment approaches for metastatic disease by targeting specific pro-oncogenic pathways.
A new analysis found that targeted cancer drugs increase the risk of fatal side effects, including bleeding and heart attacks. The study recommends caution when using these drugs in patients at high risk for complications.
Researchers found that smokers with elevated blood lead levels are at a higher risk of developing renal cell carcinoma. The study analyzed data from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study and found an association between blood lead levels and kidney cancer risk.
Researchers discovered a new commonality of chromosomal aberrations among embryonic cancers, including kidney, skeleton, and liver cancers. This finding could reveal the nature and progression of many different kinds of cancer by identifying patterns of mutation in the genome.
Researchers distinguish cancer subtypes and provide a more complete understanding of Type 2 papillary renal cell carcinoma (PRCC2), an aggressive type of kidney cancer. They also identify genes involved in clear cell renal cell carcinoma (CCRCC) development and progression, highlighting PLK1 as a promising potential therapeutic target.
Researchers identified 23 significantly mutated genes in kidney cancer, including two tumor suppressor genes. The study suggests that alteration of the ubiquitin-mediated proteolysis pathway may contribute to kidney cancer tumorigenesis by activating the hypoxia regulatory network.
A study found that organ transplant recipients have a doubled cancer risk compared to the general population, with increased risks for various types of malignancies, including non-Hodgkin lymphoma and lung cancer. The increased risk is attributed to immunosuppression and oncogenic viral infections.
A study found that long-term use of nonaspirin anti-inflammatory drugs is associated with an increased risk of renal cell cancer. The study analyzed data from two large prospective cohort studies and found a 51% increase in the relative risk of RCC among those who regularly used nonaspirin NSAIDs for more than four years.